A collaboration between the Dana-Farber Cancer Institute and the fitness tracking company Fitbit will investigate whether weight loss in women diagnosed with breast cancer can stave off recurrence.
A collaboration between the Dana-Farber Cancer Institute and the fitness tracking company Fitbit, will investigate whether weight loss in women diagnosed with breast cancer can stave off recurrence.
The trial is expected to enroll nearly 3200 women diagnosed with early stage breast cancer, who are classified either as overweight or obese, in the Breast Cancer Weight Loss (BWEL) study across North America. Disease recurrence is commonly experienced by nearly 20% of women who have breast cancer, and obesity has been identified as a common driver of malignancy in these women, and consequently poor prognosis. However, BWEL would be the first study to query whether obesity is responsible for disease recurrence in these patients.
Weight loss will be documented by Fitbit Charge HR, a fitness tracker, and participant weight will be monitored with Fitbit Aria Wi-Fi Smart Scale that tracks weight, body mass index, lean mass, and body fat percentage over time. The scale can synch with Web-based platforms to document the data. This will also help health coaches remotely track the progress—or not—of each participant.
Trial participants will receive a 2-year weight loss intervention in addition to a health education program or participate in the education program alone, as a control. Health coaches, for patients who receive the intervention, will remotely work with patients on an exercise routine and their diet.
“The increased risk of cancer recurrence linked to excess body weight threatens to limit our progress in treating breast cancer and preventing women from dying from this disease,” said Jennifer Ligibel, MD, a breast oncologist at Dana-Farber, and lead investigator of the BWEL trial, in a statement. “If this study shows that losing weight through increasing physical activity and reducing calories improves survival rates in breast cancer, this could lead to weight loss and physical activity becoming a standard part of the treatment for millions of breast cancer patients around the world.”
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Many Patients With Psoriasis in Clinical Trials Experience Nocebo Effects, Study Finds
April 18th 2024Half of patients exposed to placebo in clinical trials experienced adverse events (AEs), which may be partially explainable by nocebo effects, according to a recent review and meta-analysis.
Read More
Low-Volume Hospitals Had Higher Reoperation Rate, Postoperative Complications in CRC
April 18th 2024Patients opting for elective colorectal surgery to address colorectal cancer (CRC) could have different rates of reoperation and postoperative complications based on the size of the hospital.
Read More